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Abstract
Background: Epidemiological association of head and neck cancer with smokeless tobacco (ST) emphasizes the need to
unravel the molecular mechanisms implicated in cancer development, and identify pharmacologically safe agents for early
intervention and prevention of disease recurrence. Guggulsterone (GS), a biosafe nutraceutical, inhibits the PI3K/Akt
pathway that plays a critical role in HNSCC development. However, the potential of GS to suppress ST and nicotine (major
component of ST) induced HNSCC remains unexplored. We hypothesized GS can abrogate the effects of ST and nicotine on
apoptosis in HNSCC cells, in part by activation of PI3K/Akt pathway and its downstream targets, Bax and Bad.
Methods and Results: Our results showed ST and nicotine treatment resulted in activation of PI3K, PDK1, Akt, and its
downstream proteins - Raf, GSK3b and pS6 while GS induced a time dependent decrease in activation of PI3K/Akt pathway.
ST and nicotine treatment also resulted in induction of Bad and Bax phosphorylation, increased the association of Bad with
14-3-3fresulting in its sequestration in the cytoplasm of head and neck cancer cells, thus blocking its pro-apoptotic
function. Notably, GS pre-treatment inhibited ST/nicotine induced activation of PI3K/Akt pathway, and inhibited the Akt
mediated phosphorylation of Bax and Bad.
Conclusions: In conclusion, GS treatment not only inhibited proliferation, but also induced apoptosis by abrogating the
effects of ST / nicotine on PI3K/Akt pathway in head and neck cancer cells. These findings provide a rationale for designing
future studies to evaluate the chemopreventive potential of GS in ST / nicotine associated head and neck cancer.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) remains a
significant cause of morbidity and mortality worldwide with five
year survival rates of about 50%, marred by frequent recurrence
or formation of second primary tumors (10–25% of cases)[1,2].
On a global scale, the use of tobacco products is the major risk
factor, with smokeless tobacco (ST) consumption being linked to
the high incidence of HNSCC [3-5]. ST is used in multiple forms
namely naswar, gutkha, khaini (a mixture of ST with lime) and has
or with betel quid, been classified as a human carcinogen by
International Agency of Research in Cancer (IARC) [6,7]. The
association of smoking with HNSCC is well known, but the link
between ST use and head and neck cancer is emerging. In a recent
report, Stepanov et al. [8] identified 23 polycyclic aromatic
hydrocarbons (PAH) in ST in addition to nitrosamines and
nicotine as reported in earlier studies [7]. Nicotine enhances
proliferation, accelerates tumor growth and inhibits apoptosis in
certain types of human cancer cell lines and induces angiogenesis
in vivo by sustained activation of the mitogenic pathways [9-11].
Nicotine has been reported to inhibit apoptosis induced by opioids
and genotoxic stress induced by etoposide, cisplatin, or UV
irradiation in lung cancer cells [12,13]. In addition, nicotine
activates PI3K/Akt pathway and inhibits the pro-apoptotic
functions of Bax and Bad through phosphorylation [14,15]. These
findings prompted us to investigate whether ST (khaini) induces
PI3K/Akt pathway activation in head and neck cancer cells.
Further, identification of pharmacologically safe chemopreven-
tive agents that can suppress ST/nicotine induced PI3K/Akt
pathway in HNSCC is likely to have the potential to prevent ST
induced head and neck carcinogenesis. Guggulsterone (GS),
(4,17(20)-pregnadien- 3,16-dione), a constituent of Indian Ayur-
vedic medicinal plant Commiphora mukul is a biosafe nutraceutical
with anti-neoplastic properties [16-18]. GS has been reported to
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metastasis and reverse drug resistance, making it a potential
complementary anti-cancer agent [19-24]. GS binds to farnesoid
X receptor and has been shown to modulate expression of proteins
involved in apoptosis (IAP1, XIAP, Bfl-1/A1, Bcl-2, cFLIP,
survivin), cell proliferation (cyclin D1, c-Myc), angiogenesis and
metastasis (MMP-9, COX-2, VEGF) [25]. This sterol exerts its
biologic effects by regulation of transcription factors – nuclear
factor kappa B (NFkB), STAT-3 and C/EBP alpha, and steroid
receptors - glucocorticoid receptors and androgen receptor. Our
group and others recently demonstrated anticancer activity of GS
in HNSCC and myeloma cell lines by inhibition of NFkB and
STAT3; subsequent studies reported similar effects in other cancer
cell lines and in animal models of colon and skin cancer
[19,24,26].
In this study, we investigated the activation of PI3K/Akt
pathway in head and neck cancer cells on treatment with ST/
nicotine and its inactivation by GS. Further we challenged
activation of Akt and its downstream targets (pS6, GSK3b and
Raf), by ST/nicotine in head and neck cancer cells (SCC4) by pre-
treatment with GS.
Results
Effect of ST and nicotine activate the PI3K/Akt pathway in
head and neck cancer cells
The dose and time kinetics of ST and nicotine (addictive
component of tobacco) treatment in head and neck cancer cells
(SCC4 and HSC2), were determined by MTT assay (Figure 1A
and 1B). Similar kinetics was observed in both cell lines and the
results for SCC4 cells are shown in Figure 1. Exposure to ST and
nicotine increased cell proliferation in both the head and neck
cancer cell lines in a dose dependant manner with an optimal dose
of 20 mg/ml for ST and 10 mM for nicotine. These optimal doses
have been used in all the subsequent experiments. To investigate
the effect of ST or nicotine on the Akt pathway in HNSCC cells,
both SCC4 and HSC2 cells were treated with 20 mg/ml of ST or
with nicotine (10 mM) for different time intervals or kept untreated,
and Akt activation (Akt phosphorylation at Ser-473 and Ser-309)
was determined in the protein extracts by western blotting. Both
ST and nicotine rapidly increased Akt phosphorylation without
affecting the total Akt levels in both HSC2 and SCC4 cells
(Figure 2A and 2B respectively). These studies demonstrate that
ST and nicotine activate Akt at doses that could be physiologically
relevant. Further, our western blot analysis showed both ST and
nicotine induced a time-dependent increase in phosphorylation of
both the upstream kinases, PI3K and PDK1, as well as the
downstream targets, Raf, GSK3b, and pS6 in SCC4 cells
(Figure 2A and 2B), that reflected the rapid onset of increased
Akt phosphorylation. Similar findings were observed in both the
cell lines (SCC4 and HSC2) therefore, data for only SCC4 cells
have been shown here.
Effect of guggulsterone on ST and nicotine induced
activation of PI3K/Akt pathway
Both ST and nicotine induced stimulation of Akt pathway,
therefore, we investigated the effect of GS on ST and nicotine
induced activation of Akt pathway. SCC4 cells were treated with
GS (50 mM) for different time intervals and their protein extracts
were tested for Akt activation. As shown in Figure 3A, GS
inhibited the activation of Akt, upstream kinases PI3K, PDK1, as
well as the downstream proteins, Raf, GSK3b, and pS6. The dose
standardization of PI3K/Akt inhibitor, LY294002, was carried out
by treating the SCC4 cells with different concentrations of the
inhibitor (0.5–10 mM) for 1 h. As shown in the Figure 3B,
LY294002 (10 mM) completely inhibited the expression of
activated Akt; while no effect was observed on the total Akt
expression levels. SCC4 cells were pre-treated with GS for 4 h or
LY294002 (10 mM) for 60 min, followed by ST (20 mg/ml) for 6 h
or nicotine (10 mM) for 4 h. The results indicate that GS as well as
LY294002 blocked ST and nicotine-induced Akt pathway
activation (Figure 3C), though no effect was observed on the
expression of total Akt and GSK3b at these time points.
Guggulsterone and PI3K-specific inhibitor LY294002
block ST and nicotine induced Bad and Bax
phosphorylation
Both ST and nicotine potently stimulated serine phosphoryla-
tion of Bax and Bad in a time dependent manner (Figure 4A and
4B) resulting in abrogation of their pro-apoptotic function. To
demonstrate a functional role of Akt as the physiological ST and
nicotine activated Bax and Bad kinase, LY294002, a PI3K specific
inhibitor that can block the PI3K/Akt signaling pathway, was
used. SCC4 cells were pre-treated with LY294002 (10 mM) for
60 min or 50 mM GS for 4 h followed by ST (20 mg/ml) for 6 h or
with nicotine (10 mM) for 4 h. GS as well as LY294002 blocked ST
and nicotine induced Bax and Bad phosphorylation (Figure 4A
and 4B). No effect on expression of total Bad and Bax was
observed at these time points. These findings suggest that
Figure 1. Dose and Time dependent kinetics of ST and nicotine treatment on SCC4 cells using MTT assay. Cells were treated with (A) ST
(1-500 mg/ml ), (B) nicotine (1-100 mM) for 24–96 h. Figure depicts average of three experiments done independently.
doi:10.1371/journal.pone.0014728.g001
GS Inhibits PI3K/Akt Pathway
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lation by GS may restore the pro-apoptotic function of these
molecules.
Akt is co-localized with Bax in cytoplasm
To assess a potential direct role for Akt as a physiological Bax
kinase, sub-cellular distribution of Akt and Bax were assessed by
immunofluorescence staining. Bax was primarily co-localized with
Akt in the cytoplasm of SCC4 cells (Figure 5A) suggesting that
both ST and nicotine activated Akt has the potential to directly
phosphorylate and inactivate Bax in SCC4 cells.
Phosphorylation of Bax and Bad results in retention of
these proteins in cytosol and failure to target
mitochondria
Our results demonstrated that ST and nicotine can induce Bax
(Ser-184) and Bad (ser-136) phosphorylation, and phosphorylation
at these sites resulted in inactivation of the pro-apoptotic function
of Bax and Bad. It is well known that the pro-apoptotic activity of
Bax and Bad is dependent on its cytosolic or mitochondrial
localization. To test whether phosphorylation of Bax and Bad
effects its sub-cellular localization, SCC4 cells were kept untreated
or treated with GS (50 mM) for 4 h, ST (20 mg/ml) for 6 h and
nicotine (10 mM) for 4 h. Sub-cellular fractionations were
performed to isolate mitochondria and cytosol as described under
material and methods. In untreated SCC4 cells, majority of Bax
and Bad was found in the cytosol, and only a small amount of
these proteins, was localized in the mitochondria (Figure 5B). In
GS treated cells majority of these proteins were observed in the
mitochondrial fraction. In contrast, in both ST and nicotine
treated cells, Bax and Bad were predominantly observed in the
cytosol (Figure 5B).
Notably, pre-treatment of SCC4 cells with GS (50 mM) for 4 h,
followed by ST (20 mg/ml) treatment for 6 h or nicotine (10 mM)
for 4 h, showed a shift in localization of Bax and Bad and majority
of these proteins were observed in the mitochondrial fraction
(Figure 5B). To confirm the purity of the subcellular fractions
obtained, succinate dehydrogenase, a protein exclusive to the
mitochondria, was assessed by western blotting. Succinate
dehydrogenase, was detected only in the mitochondrial fraction
and not in the cytosol (Figure 5B), confirming the purity of the
Figure 2. ST and nicotine - induced Akt pathway activation. SCC4 cells (2–3610
6) were treated with (A) ST (20 mg/ml) or (B) nicotine (10 mM),
for the indicated time intervals and whole-cell extracts were prepared. Whole-cell extracts (60 mg protein) were resolved on 10% SDS-PAGE,
electrotransferred to a PVDF membrane and non-specific binding was blocked with 5% non-fat milk overnight. Protein expression was determined by
probing with phospho-specific antibodies for pAkt (thr-309), pAkt (ser-473). pGSKb3, pRaf, pPDK1 and Akt using enhanced chemiluminescence
method. Western blotting for a-tubulin was done to show equal protein loading.
doi:10.1371/journal.pone.0014728.g002
GS Inhibits PI3K/Akt Pathway
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control to ensure equal protein loading in all the lanes.
ST and nicotine induced Bad phosphorylation enhances
interaction with 14-3-3f
Bad phosphorylation (ser-136) promotes its translocation from
mitochondria into cytosol and interaction with the scaffold protein
14-3-3. To assess whether ST or nicotine affect Bad association,
SCC4 cells were treated with ST (20 mg/ml) or nicotine (10 mM)
for different time intervals. Co-immunoprecipitation of 14-3-3f
and Bad showed a time dependent increase in bound pBad in the
immunocomplexes (IP) of 14-3-3f indicating association between
14-3-3f and pBad (Figure 6A and 6B), on treatment with ST and
nicotine respectively. Similar results were observed in reverse
immunoprecipitation assays, western blotting was done for 14-3-3f
in immunocomplexes obtained using pBad specific antibody,
confirming the interaction of 14-3-3f with pBad (Figure 6A and
6B). These results suggest ST and nicotine induced Bad
phosphorylation resulted in sequestering Bad in the cytoplasm,
functionally blocking its pro-apoptotic function.
Discussion
Tobacco in various forms is one of the main etiological factors
for development and progression of HNSCC. Aberrant expression
of genes involved in cell growth, survival, angiogenesis, invasion
and metastasis in ST associated head and neck carcinogenesis has
been reported by our group and others [27-31]. In this study, we
demonstrated activation of Akt in HNSCC cells treated with ST/
nicotine, evidenced by sustained phosphorylation of Akt at serine
473 and threonine 308, as well as its downstream substrates (pS6,
GSK3b, pRaf), in a time-dependent manner. Both ST and
nicotine also induced the phosphorylation of the upstream kinase
PDK1 (Ser241), and p85 subunit of another upstream kinase,
PI3K in SCC4 cells. These observations are supported by the
earlier reports showing activation of PI3K/Akt in cultured cortical
neurons, normal human bronchial and small airway epithelial cells
in response to nicotine treatment [11,32-34]. Further, we showed
both ST and nicotine activated Akt, induced Bad (Ser136) and Bax
phosphorylation (Ser184) resulting in cytoplasmic retention of
these proteins. However, treatment with LY294002, a PI3K/Akt
inhibitor, potently inhibited ST and nicotine induced phosphor-
Figure 3. Guggulsterone inhibits constitutive and ST or nicotine induced Akt pathway activation. SCC4 cells (2–3610
6) were treated
with (A) GS (50 mM) for the indicated time intervals and/ or (B) with LY294002 at different concentrations for 1 h. (C) SCC4 cells (2–3610
6) were pre-
treated with 50 mM GS for 4 h or with LY294002 (10 mM) for 1 h and stimulated with ST (20 mg/ml) for 6 h, or with nicotine (10 mM) for 4 h. Sixty
micrograms of proteins from whole-cell extracts were resolved on 10% SDS-PAGE, electrotransferred to a PVDF membrane followed by blocking with
5% non-fat milk overnight. Protein expression was determined by probing with specific antibodies using enhanced chemiluminescence method.
doi:10.1371/journal.pone.0014728.g003
GS Inhibits PI3K/Akt Pathway
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mitochondrial relocalization of these proteins, further strengthen-
ing our observation that ST and nicotine induced phosphorylation
of Bad (Ser-136) and Bax (Ser-184) by activation of PI3K/Akt.
Interestingly, both ST and nicotine induced phosphorylation of
Bad (Ser-136) in SCC4 cells increased its association with 14-3-3f
as revealed by co-IP assays. This results in sequestration of Bad in
the cytoplasm, thus inhibiting the intrinsic pathway of apoptosis.
Earlier reports have shown phosphorylation on either Ser112 or
Ser136 facilitates formation of a complex between Bad and 14-3-
3s in the cytosol, blocking their interaction with Bcl2/Bcl-xl in the
mitochondria [35,36].
Recently, we demonstrated overexpression of PI Synthase, PI3-
K and cyclin D1 in ST treated cells from oral lesions and oral
cancer [37]. Further, analyzing clinical specimens from oral
leukoplakic lesions without dysplasia, with dysplasia and oral
squamous cell carcinomas (OSCCs), we provided the first evidence
of increased expression of PI Synthase in early stages of oral
precancer and cancer and its correlation with tumor dedifferen-
tiation and tobacco consumption [37]. Here in we extended these
findings to demonstrate GS could inhibit the induction of PI3K/
Akt by ST and nicotine.
Thus, inhibiting the induction of Akt activity by ST tobacco
components might be a valuable approach to mitigate the effects
of tobacco in consumers at risk for the development of HNSCC,
and/or in HNSCC patients who continue to smoke or use ST
products. In this respect, we observed that GS suppressed the
phosphorylation of Akt (Ser473 and Thr308), PDK1 (Ser241) and
p85 subunit of PI3K, leading to decreased phosphorylation of
GSK3b, pRaf, pS6, the downstream targets of Akt. Notably, our
study revealed that GS not only inhibited the constitutive PI3K/
Akt pathway, but its pre-treatment abrogated both ST and
nicotine induced activation of PI3K/Akt pathway. ST and
nicotine abrogated the pro-apoptotic effects of Bax/Bad by
phosphorylation and sequestering in cytoplasm, however GS
pre-treatment inhibited the effect of ST and nicotine, targeting
Bax and Bad to the mitochondria, inducing apoptosis. However,
the effect of GS is not specific and limited to head and neck cancer
cells only. We and others have shown the anti-cancer effects of GS
in a variety of cancer cell types namely, head and neck; leukemia,
multiple myeloma, lung, melanoma, ovarian, gut derived adeno-
carcinoma, colorectal, colon, skin, prostate, esophagus, and breast
[19,21-24,38-43].
In conclusion, our study demonstrated that both ST and
nicotine promote survival of human head and neck cancer cells
SCC4, by inactivating the pro-apoptotic functions of Bax and Bad
via its phosphorylation and sequestering these proteins in
cytoplasm. GS not only inhibits constitutively active PI3K/Akt
pathway, but also inhibits ST and nicotine induced activation of
this pathway and promotes apoptosis signals in these cells
Figure 4. Guggulsterone and PI3K-specific inhibitor LY294002 block ST and nicotine induced Bad and Bax phosphorylation. SCC4
cells (2–3610
6) were treated with (A) ST (20 mg/ml) or (B) Nicotine (10 mM) for the indicated time intervals. SCC4 cells were pre-treated with LY294002
(10 mM) for 60 min, or 50 mM GS for 4 h, followed by ST (20 mg/ml) for 4 h, or with nicotine (10 mM) for 4 h, and whole-cell extracts were prepared.
Sixty microgram proteins from whole-cell extracts were resolved on 10% SDS-PAGE, electrotransferred to a PVDF membrane followed by blocking
with 5% non-fat milk overnight. Protein expression was determined using enhanced chemiluminescence method and probed by antibodies against
pBad and pBax. The blots were stripped and reprobed for Bax and Bad proteins.
doi:10.1371/journal.pone.0014728.g004
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agent for ST induced head and neck carcinogenesis.
Materials and Methods
Antibodies and Reagents
z-Guggulsterone (GS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), propidium iodide (PI) were purchased
from Sigma-Aldrich (St. Louis, MO). Mouse monoclonal antibody
against Bax (sc-7480); rabbit polyclonal antibody against 14-3-3f
(sc-1019), pPI3K p85 antibody (Tyr-508, sc-12929R) were
purchased from Santa Cruz Biotechnology, Santa Cruz, CA.
Rabbit monoclonal antibody against phospho-Akt (Ser 473, cat-
9271), phospho-Akt (Thr 308, cat-9275), Akt (cat-9272), phospho-
GSK-3b (Ser 9, cat-9336), phospho-Raf (Ser 259, cat-9421),
phospho-PDK1 (Ser 241, cat-3061), PI3-kinase inhibitor
LY294002 (cat-9901) were all purchased from Cell Signaling
Technology. For co-localization studies, goat anti-rabbit Alexa
FluorH 594 (Cat no A-11012) was purchased from Invitrogen
(Carlsbad, CA). Goat anti-mouse FITC (Cat no. F2012) was
purchased from Sigma (St. Louis, MO). Protein A-sepharose beads
wereobtained from GEHealthcare Biosciences, (Uppsala, Sweden).
Cell culture
Human head and neck squamous carcinoma cell lines, SCC4
was obtained from American Type Culture Collection (ATCC)
and HSC2 (JCRB0622) was obtained from Health Science
Research Resources Bank (HSRRB), Japan [44,45]. Both these
head and neck cancer cell lines are known to harbor mutant
p53. SCC4 cells have a point mutation at codon 51 CCC to
TCC and HSC2 cells have a mutation in intron 6 [44,45].
HSC-2 cells harbor mutated PIK3CA (H1047R) [46]. Both
head and neck cancer cell lines (SCC4 and HSC2) were grown
in monolayer cultures in Dulbecco’s modified eagle medium
(DMEM) (Sigma, St. Louis, MO) supplemented with 10% Fetal
bovine serum (FBS) (Sigma), 1 mM L-glutamine, 1X sodium
pyruvate, 1X vitamins, 1 mM minimum essential medium
(MEM), 100 mg/ml streptomycin and 100 U /ml penicillin in
a humidified incubator (5% carbon-dioxide, 95% air) at 37 uC
as described earlier [47].
Preparation of Smokeless Tobacco Extract (ST)
Commonly used brand of cured tobacco (Khaini) was
purchased from the local market. 25 g of tobacco was finely
powdered and homogenized in 225 ml of distilled water. Mixture
was stirred on a magnetic stirrer for two hours and then allowed to
stand for 24 hrs at 37 uC. Thereafter, supernatant was collected
after centrifugation at 5000 g for 20 minutes. The extract was
sterilized by passing it through a 0.22 mm filter and stored at 4 uC
till use. The final concentration of tobacco in aqueous extract was
estimated to be 2.7 g% [48].
Figure 5. (A) AKT is co-localized with Bax in cytoplasm. SCC4 cells (5610
3) were plated on coverslips and incubated with a mouse antibody
against human Bax and a rabbit antibody against human AKT antibodies. Alexa flourH594 -conjugated anti-rabbit (red) and Fluorescein
isothiocyanate-conjugated (green) anti-mouse secondary antibodies were used to visualize Akt (red) and Bax (green) localization patterns using a
fluorescent microscope. Panel (i) DAPI stained nuclei in blue color; (ii) cytoplasmic expression of Bax; (iii) cytoplasmic expression of Akt protein; and
(iv) merged photomicrograph (ii) and (iii) showing co-localization of Bax and Akt. (B) Phosphorylation of Bax at (Ser-184) and Bad (Ser-136) results in
retention of Bax and Bad in cytosol. SCC4 cells were kept untreated or treated with 50 mM GS for 4 h, ST (20 mg/ml) for 6 h, 10 mM nicotine for 4 h.
SCC4 cells were pre-treated with 50 mM GS for 4 h, followed by ST for 6 h or with nicotine for 4 h. Cytoplasmic (C) and Mitochondrial (M) extracts
were prepared as described in materials and methods and separated on 10% SDS-PAGE. Proteins were then electro-transferred on PVDF membrane
followed by blocking with 5% non-fat milk overnight. Blots were incubated with specific antibodies against Bax and Bad. Protein expression was
determined using enhanced chemiluminescence method. Purity of the subcellular fractions obtained was determined using western blot for
mitochondrial protein, succinate dehydrogenase. b-actin was used as a loading control.
doi:10.1371/journal.pone.0014728.g005
GS Inhibits PI3K/Akt Pathway
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Head and neck cancer cells (5610
3/well) were plated in a 96-
well plate for 24 hrs. Cells were incubated in triplicates in the
presence of medium containing ST/nicotine or 0.02% of DMSO
which served as a vehicle control in a final volume of 100 ml for
24–96 hrs at 37 uC. Cell death was measured by adding 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at
37 uC for 3–4 h. The formazan crystals were dissolved in 100 mlo f
dimethylsulphoxide (DMSO) and optical density (OD) was
measured at wavelength of 570 nm. The percentage cell death
was calculated individually for each dose as follows: (ODcontrol
2ODtreated/ODcontrol)6100, as described earlier [49].
Western blotting and Co-immunoprecipitation (Co-IP)
assay
Co-immunoprecipitation (Co-IP) assays and WB were carried
out as described by us previously [39]. Whole-cell lysates were
prepared from GS (50 mM) or nicotine (10 mM) treated SCC4 cells
and protein concentration was determined using the Bradford
reagent (Sigma) and equal amounts of proteins (50 mg/lane) were
resolved on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel.
The proteins were then electro-transferred onto polyvinylidenedi-
fluoride (PVDF) membrane. After blocking with 5% non-fat milk
in Tris-buffered saline (TBS, 0.1 M, pH=7.4), blots were
incubated with specific antibodies as per manufacturer’s recom-
mended protocol at 4 uC overnight. Protein abundance of a-
tubulin (Santa Cruz Biotechnology, CA) served as a control for
protein loading in each lane. Membranes were incubated with
HRP-conjugated secondary antibodies, (DAKO Cytomation,
Glostrup, Denmark), diluted at an appropriate dilution in 1%
BSA, for 2 h at room temperature. After each step, blots were
washed three times with Tween (0.1%)-Tris-buffer saline (TTBS).
Protein bands were detected by the enhanced chemiluminescence
method (ECL, Santa Cruz Biotechnology, CA) on XO-MAT film.
Co-IP assays were carried out as described earlier.
Figure 6. ST and nicotine induces Bad phosphorylation enhances interaction with 14-3-3f. SCC4 were treated with (A) ST (20 mg/ml) or
(B) with nicotine (10 mM) for different time intervals and immunoprecipitation assays were carried out using whole cell lysates and analyzed by
western blotting as described in Materials and Methods. 14-3-3f was immunoprecipitated using specific antibody and the bound pBad protein co-
precipitated with 14-3-3f was determined by western blot analysis. Reverse immunoprecipitation assays were carried out in which pBad was
immunoprecipitated, followed by western blotting analysis of 14-3-3f using a specific antibody against this protein. (C) Figure shows the
hypothetical model for inhibition of ST / nicotine induced activation of PI3K/Akt pathway by GS. Our results showed treatment with ST and /or
nicotine activates Akt (phosphorylated at Ser-473 and Ser-309) resulting in phosphorylation of its downstream targets Raf, GSK3b, and pS6, whereas
GS treatment inhibits activation of Akt pathway. Interestingly, pre-treatment of head and neck cancer cells with GS inhibits activation of Akt and its
downstream targets (Raf, GSK3b, and pS6) on exposure to ST / nicotine. GS pre-treatment also releases Bad from inhibitory action of 14-3-3f, thereby
activating intrinsic pathway of apoptosis. Thus, our results demonstrated GS as a potential therapeutic agent for ST-induced head and neck
carcinogenesis.
doi:10.1371/journal.pone.0014728.g006
GS Inhibits PI3K/Akt Pathway
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mitochondria
Head and neck cancer cells (2610
7) were treated, harvested and
washed once with cold 1X PBS and resuspended in isotonic
mitochondrial buffer (210 mM mannitol, 70 mM sucrose, 1 mM
EGTA, 10 mM Hepes, pH 7.5, 0.1% BSA) containing protease
inhibitor cocktail. The resuspended cells were homogenized with a
polytron homogenizer operating for four bursts of 10 s each at a
setting of 5 and then centrifuged at 2000 g for 3 min to pellet the
nuclei and unbroken cells. The supernatant was centrifuged at
13,000 g for 10 min to pellet mitochondria as described [50]. The
supernatant was further centrifuged at 15,000 g to pellet light
membranes. The resulting supernatant contained the cytosolic
fractions. The mitochondria was washed with mitochondrial
buffer twice, resuspended with 1% Nonidet P-40 lysis buffer,
rocked for 60 min, and then centrifuged at 13,000 g for 10 min at
4 uC. The supernatant containing mitochondrial proteins was
collected. Protein (100 mg) from each fraction was subjected to
12% SDS-PAGE and analyzed by western blot analysis using anti-
cytochrome c antibody. The purity of the fractions was confirmed
by assessing localization of fraction-specific proteins including
succinate dehydrogenase for mitochondria.
Co-localization studies of Akt and Bax in oral cancer cells
using confocal laser scan microscopy
Head and neck cancer cells, SCC4 and HSC2, were grown on
coverslips in DMEM medium supplemented with 10% FBS at
37 uC and processed for confocal laser scan microscopy as
described by us previously [51]. Cells were rinsed in Dulbecco’s
PBS (DPBS), fixed in methanol for 5 min at 220 uC and
incubated with specific primary antibodies, mouse monoclonal
anti-Bax and rabbit monoclonal anti-Akt antibody, incubated as a
cocktail at 4 uC overnight. After rinsing in phosphate buffer saline-
0.1% Tween (PBST, 1X) the coverslips were incubated with anti-
mouse FITC conjugated/anti-rabbit Alexa flourH594 conjugated
secondary antibody for 45 min at 37 uC in the dark. Coverslips
were washed and counterstained with DAPI for 30 sec. A mouse
antibody against human Bax, a rabbit antibody against human
Akt, and fluorescein isothiocyanate-conjugated anti-mouse (green)
or rhodamine-conjugated anti-rabbit (red) secondary antibodies
were used so that cells could be stained simultaneously without
cross-reaction. In negative controls, the primary antibodies were
replaced by non-immune mouse IgG of the same isotype to ensure
specificity (data not shown). Thereafter, the slides were rinsed and
mounted in fluorescence mounting medium and examined with
Lieca TCS SP2 confocal laser scanning microscopy (CLSM).
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